Hospital-Acquired Infection Diagnostics Market And its Growth prospect in the Near Future - PowerPoint PPT Presentation

About This Presentation

Hospital-Acquired Infection Diagnostics Market And its Growth prospect in the Near Future


The development of technologically advanced products is positively impacting the hospital-acquired infection (HAI) diagnostics domain. Advancements in technology have revolutionized the HAI diagnostics domain by enabling the development of products that offer reliable results in less time. For instance, in 2017, Roche Diagnostics launched the cobas Liat PCR system with four assays with the ability to conduct a real-time PCR nucleic acid test for Clostridium difficile detection in 20 minutes. – PowerPoint PPT presentation

Number of Views:97


Transcript and Presenter's Notes

Title: Hospital-Acquired Infection Diagnostics Market And its Growth prospect in the Near Future

Hospital-Acquired Infection Diagnostics Market to
Reach 4,386.6 Million by 2023
The growth in the market will be led by the
increase in incidences of infections caused in
clinical settings, especially in developing
economies owing to their poor hygiene facilities.
Insights on market segments
On the basis of test type, the HAI diagnostics
industry has been categorized molecular
diagnostics, urinalysis, and immunoassay. Due to
the high prevalence rate of HAI such as,
bloodstream infections, surgical site infections,
gastrointestinal Infections, and urinary tract
infections (UTI), the immunoassay segment was the
highest contributor accounting for 1,195.0
million in 2016 and is expected to reach 1,686.2
million by 2023. In terms of product, the HAI
diagnostics market has been categorized into
instrument and reagents and consumables. The
reagents and consumables dominated the market in
2016 with a share of 63.1. The rise in the
number of patients suffering from various
infectious diseases such as bloodstream
infections, surgical site infections,
gastrointestinal infections, urinary tract
infections (UTI), which increases the demand for
reagents consumables with growth in molecular
diagnostic testing volumes. It is also expected
to maintain the same trend throughout the
forecast period, registering a high CAGR of 8.0
during 2017-2023.
Browse Detailed Report Summary with In-depth TOC
on "Hospital-Acquired Infection (HAI) Diagnostics
Market by Product (Reagents and Consumables,
Instruments), by Test Type (Immunoassay,
Molecular Diagnostics, Urinalysis), by
Application (Drug-Resistance, Disease), by
Infection Type (UTIs, Surgical Site, Bloodstream,
Gastrointestinal Hospital Acquired Pneumonia), by
End User (Hospitals, Clinics, ASCs), by Geography
(U.S., Canada, Mexico, Germany, France, U.K.,
Italy, Spain, Japan, China, Australia, South
Korea, India, Brazil, Saudi Arabia, South Africa)
Global Market Size, Share, Development, Growth,
and Demand Forecast, 20162023" at
North America to exhibit the largest revenue in
terms of size
The HAI diagnostics market in North America was
the highest contributor accounting for 1,022.9
million in 2016, attributed to the increase in
geriatric population. Adoption of advance HAI
diagnostics techniques for disease diagnosis also
provides opportunity for the growth of the market
in North America.
Major players undergo acquisitions to gain a
larger market
Key players in the HAI diagnostics industry are
acquiring other players, to gain a larger market
share. For instance, in October 2017, Abbott
Laboratories intends to close the acquisition of
Alere Inc. The announcement follows receipt of
all regulatory clearances necessary for closing.
The acquisition is intended to expand Abbott
Laboratories global point of care testing
portfolio. Similarly, in April 2017, Becton,
Dickinson and Company announced the acquisition
of Caesarea Medical Electronics, an Israel based
global infusion pump systems manufacturer. The
acquisition would expand Infusion Portfolio for
ambulatory, home care and specialty
applications. Some of the other key players
operating in the HAI diagnostics market are
AstraZeneca plc, Bayer AG, Daiichi Sankyo Co.
Ltd., Danaher Corporation, Hologic Inc., Johnson
Johnson, OpGen Inc., and F. Hoffmann-La Roche
Download report sample at
For information regarding permissions and other
queries Kindly write to
US/Canada Toll-Free 1-888-778-7886
Write a Comment
User Comments (0)